LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Search

CareDx Inc

Geschlossen

BrancheGesundheitswesen

18.68 0.05

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

18.68

Max

18.96

Schlüsselkennzahlen

By Trading Economics

Einkommen

10M

1.7M

Verkäufe

13M

100M

KGV

Branchendurchschnitt

14.68

108.767

Gewinnspanne

1.674

Angestellte

644

EBITDA

11M

7.2M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+33.26% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

29. Apr. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

214M

1B

Vorheriger Eröffnungskurs

18.63

Vorheriger Schlusskurs

18.68

Nachrichtenstimmung

By Acuity

50%

50%

139 / 352 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Neutral Evidence

CareDx Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

27. Feb. 2026, 23:53 UTC

Heiße Aktien

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

27. Feb. 2026, 22:23 UTC

Akquisitionen, Fusionen, Übernahmen

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

28. Feb. 2026, 21:36 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28. Feb. 2026, 15:20 UTC

Ergebnisse

Berkshire's Abel Pledges to Follow Buffett's 'Framework' in First Shareholder Letter -- 2nd Update

28. Feb. 2026, 14:43 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28. Feb. 2026, 14:38 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Berkshire's Abel Pledges to Follow Buffett's 'Framework' in First Shareholder Letter -- Update

28. Feb. 2026, 13:47 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28. Feb. 2026, 13:44 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Berkshire Hathaway Earnings Slip on Decline in Insurance Results -- WSJ

28. Feb. 2026, 13:14 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28. Feb. 2026, 02:32 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Calpers Buys Into Hot Chip And Quantum Stocks -- Barrons.com

28. Feb. 2026, 02:00 UTC

Akquisitionen, Fusionen, Übernahmen

Six Months, 9 Offers and $81 Billion. How Hollywood's Nasty Takeover Was Won. -- WSJ

28. Feb. 2026, 02:00 UTC

Akquisitionen, Fusionen, Übernahmen

Six Months, 9 Offers and $81 Billion. How -2-

28. Feb. 2026, 00:01 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Issuing $47 Billion of Equity at Big Premium to Stock Price for Warner Bros. Deal -- Barrons.com

27. Feb. 2026, 23:46 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

27. Feb. 2026, 23:33 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

27. Feb. 2026, 21:50 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Tech, Media & Telecom Roundup: Market Talk

27. Feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

27. Feb. 2026, 21:30 UTC

Ergebnisse

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

27. Feb. 2026, 21:30 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

27. Feb. 2026, 21:20 UTC

Akquisitionen, Fusionen, Übernahmen

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

27. Feb. 2026, 21:17 UTC

Ergebnisse

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27. Feb. 2026, 21:10 UTC

Akquisitionen, Fusionen, Übernahmen

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

27. Feb. 2026, 21:09 UTC

Akquisitionen, Fusionen, Übernahmen

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

27. Feb. 2026, 21:00 UTC

Ergebnisse

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

27. Feb. 2026, 20:31 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix Receives $2.8B Termination Fee Under Terminated Warner Bros. Discovery Deal

27. Feb. 2026, 20:24 UTC

Market Talk

Oil Gains on Increased Risk of U.S.-Iran Conflict -- Market Talk

27. Feb. 2026, 20:23 UTC

Market Talk

U.S. Natural Gas Futures Post Modest Gains -- Market Talk

27. Feb. 2026, 20:12 UTC

Market Talk

Nike Seen With Further Challenges in China -- Market Talk

27. Feb. 2026, 19:44 UTC

Market Talk

Gold Caps Historic Month -- Market Talk

27. Feb. 2026, 19:39 UTC

Ergebnisse

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

Peer-Vergleich

Kursveränderung

CareDx Inc Prognose

Kursziel

By TipRanks

33.26% Vorteil

12-Monats-Prognose

Durchschnitt 25 USD  33.26%

Hoch 28 USD

Tief 21 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für CareDx Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

5 ratings

2

Buy

3

Halten

0

Sell

Technischer Score

By Trading Central

14.77 / 18.49Unterstützung & Widerstand

Kurzfristig

Neutral Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

Weak Bearish Evidence

Stimmung

By Acuity

139 / 352 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat